Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Royce

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Opinion in Oncology|July 23, 1999
Novel chemotherapeutic agents for gastrointestinal cancersM E Royce, R Pazdur
Drugs & Aging|October 24, 2000
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?M E Royce, P M Hoff, R Pazdur
Current Oncology Reports|December 21, 2000
Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexedM E Royce, P M Hoff, R Padzur
Current Oncology Reports|December 21, 2000
Novel oral chemotherapy agentsM E Royce, P M Hoff, R Pazdur
American Journal of Clinical Oncology|July 28, 2001
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancerM L Wang, W K Yung, M E Royce, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
Colorectal cancer: chemotherapy treatment overviewM E Royce, D Medgyesy, T H Zukowski, et al.
Oncology|August 7, 1999
Fluoropyrimidines: a critical evaluationR A Brito, D Medgyesy, T H Zukowski, et al.
American Journal of Clinical Oncology|February 20, 1999
Phase II trial of docetaxel for cholangiocarcinomaR Pazdur, M E Royce, G I Rodriguez, et al.
Nucleic Acids Research|September 12, 1988
Identification of DNA sequences required for mouse APRT gene expressionM K Dush, M R Briggs, M E Royce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analogM E Royce, P M Hoff, P Dumas, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Opinion in Oncology|July 23, 1999
Novel chemotherapeutic agents for gastrointestinal cancersM E Royce, R Pazdur
Drugs & Aging|October 24, 2000
Progress in colorectal cancer chemotherapy: how far have we come, how far to go?M E Royce, P M Hoff, R Pazdur
Current Oncology Reports|December 21, 2000
Novel chemotherapy agents for colorectal cancer: oral fluoropyrimidines, oxaliplatin, and raltitrexedM E Royce, P M Hoff, R Padzur
Current Oncology Reports|December 21, 2000
Novel oral chemotherapy agentsM E Royce, P M Hoff, R Pazdur
American Journal of Clinical Oncology|July 28, 2001
Capecitabine for 5-fluorouracil-resistant brain metastases from breast cancerM L Wang, W K Yung, M E Royce, et al.
Oncology (Williston Park, N.Y.)|February 24, 2001
Colorectal cancer: chemotherapy treatment overviewM E Royce, D Medgyesy, T H Zukowski, et al.
Oncology|August 7, 1999
Fluoropyrimidines: a critical evaluationR A Brito, D Medgyesy, T H Zukowski, et al.
American Journal of Clinical Oncology|February 20, 1999
Phase II trial of docetaxel for cholangiocarcinomaR Pazdur, M E Royce, G I Rodriguez, et al.
Nucleic Acids Research|September 12, 1988
Identification of DNA sequences required for mouse APRT gene expressionM K Dush, M R Briggs, M E Royce, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2001
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analogM E Royce, P M Hoff, P Dumas, et al.
Pageof 1